Full Text (PDF)
Abstract
Aim: Angiogenesis is an important factor in tumoral progression, metastasis and invasion. More recently, it has also been found to play a particular role in hematological malignancies. Methods: In this study, 45 patients harboring hematological malignancies (15 acute myeloid leukemia (AML), 10 acute lymphoblastic leukemia (ALL), 10 multiple myeloma (MM), 10 chronic myeloid leukemia (CML)) were compared with 20 healthy individuals matched according to age and sex, regarding serum vascular endothelial growth factor (VEGF, a marker for angiogenesis) levels. Results: The difference between serum VEGF levels of the study group (338.4 ± 587.6 pg/mL) and the control group (69.9 ± 24.4 pg/mL) was statistically significant (p<0.05). The highest serum VEGF level (1099.7±906.8 pg/mL) was found in CML subgroup. Conclusion: Serum VEGF levels of the patients with hematological malignancies were significantly higher compared to controls. Further studies are needed to determine the exact role of VEGF in the development and progression of the hematological malignancies and therapeutic implications of this finding.
License
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Article Type: Original Article
EUR J GEN MED, Volume 3, Issue 3, July 2006, 116-120
https://doi.org/10.29333/ejgm/82390
Publication date: 15 Jul 2006
Article Views: 1291
Article Downloads: 742
Open Access References How to cite this article